Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ember strikes alliance with Brigham & Women's Hospital

Executive Summary

In its third deal with a tech transfer entity this year, metabolic disease-focused start-up Ember Therapeutics Inc. has received an exclusive option from Brigham and Women’s Hospital to two small molecule targets--retinaldehyde dehydrogenase 1 (Aldh1a1) and thioesterase superfamily member 1 (Them1)--that are associated with brown fat pathways and mechanisms.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies